Brexpiprazole for the Treatment of Agitation in Alzheimer's Disease Dementia: Clinical Uncertainties and the Path Forward.

Brexpirazole was approved for the treatment of nonpsychotic agitation in Alzheimer's disease (AD) dementia by the United States Food and Drug Administration (FDA) in May 2023 after three phase 3 clinical trials found brexpiprazole 2 to 3 mg/day to be an effective and well-tolerated treatment for agitation in AD dementia, albeit with small effect sizes. It appeared to especially benefit dementia patients with severe agitation/aggression, but it took between 6 and 12 weeks across the three studies for the medication to separate from placebo. However, much remains unknown about its place in the psychopharmacological armamentarium for the treatment of AD dementia-related agitation, including the optimal duration of a brexpiprazole trial, bridging options during the time it takes for brexpiprazole to become effective, and whether it should be continued in the presence of or upon emergence of psychosis during treatment.

When and How to Treat Agitation in Alzheimer's Disease Dementia With Citalopram and Escitalopram.

Agitation is a common neuropsychiatric symptom (NPS) in the early and middle stages of Alzheimer's disease (AD) dementia, which is difficult to treat and causes much distress. The U.S.

Childhood autism in tuberous sclerosis.

The article reports two cases of childhood autism in tuberous sclerosis (TS). Certain atypical features are highlighted. The probands did not show the common seizure types associated with either TS or autism.

Postictal mania following primary generalized seizures.

A 29 year old male with primary generalized seizures for 13 years stopped his anticonvulsants leading to an increase in seizure frequency. Five months later he developed a severe manic episode postictally which responded well to a combination of neuroleptics and anticonvulsants. Postictal psychoses usually follow complex partial seizures.

Comparison of conduct disorder and hyperkinetic conduct disorder : a retrospective clinial study from north India.

In a retrospective descriptive study of hyperkinetic conduct disorders (HCD) and conduct disorders (CD), as per ICD-10 diagnostic criteria, their clinical and phenomenological correlates were compared; with an aim of describing their distinctive clinical profiles. 20 cases of HCD and 25 cases of CD were compared on socio-demographic variables, temperament and specified clinical variables. The two groups differed in terms of the HCD group having younger age of onset, a more gradual development of and longer duration of conduct symptoms as compared to CD children.

Burden of care in patents of children suffering from haematological malignancies.

The burden of cars experienced by the parents of children suffering from haematological malignancies was the focus of the present investigation. Two groups of children-one with acute lymphoblastic leukaemia (N=23) and the other with hodgkin's disease (N=14) comprised the study sample. The key relatives of these children who also were the caregivers were assessed on a schedule of stressful life events, locus of control, burden of care, and neuroticism.

The relationship of insight to psychopathology in schizophrenia: a cross-sectional study.

Insight plays an important role in the management of Schizophrenia. The study was undertaken to assess the cross-sectional relationship of clinical variables and psychopathology to insight, using the BPRS and the Insight Schedule. The study sample consisted of 59ICD-10 Schizophrenics with a mean duration of illness of 41.

A study of comorbidity in psychoactive substance dependence patients.

The study assessed the lifetime prevalence of comorbidity in forty three DSM III-R opioid and alcohol dependent patients. A total lifetime prevalence rate of 60.5% was found.